Medical scribes reduce documentation time by 3.2 minutes per patient encounter

One of the main complaints about electronic medical records (EMRs) from physicians is the time documentation takes away from the patient visit. In a study published in the Journal of the American Medical Association Dermatology, researchers evaluate the effect medical scribes have on clinical documentation.

While EMRs have the potential to increase efficiency, documentation has increased physician burnout and decreased job satisfaction. In this study, researchers evaluated how employing medical scribes affects clinical documentation time and physician satisfaction.

Led by Vinod Manbudiri, MD, researchers used a quality improvement program in dermatology offices to measure documentation time before and after the programs implementation. The study enrolled 39 dermatologists, 12 of which received a scribe in 19 weekly half-day sessions. Each scribe was enrolled in dermatology-specific training and shadowed a lead scribe to learn documentation preferences.

Results showed that before the program's implementation, the average time spent doing clinical documentation was 60 to 89 minutes a session with 30 percent of physicians spending more than two hours per session. After implementation, dermatologists were able to reduce documentation time to 36 minutes per session, which equated to 3.2 fewer minutes per patient encounter.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.